Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models
Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models
以心元治疗学公司展开研究,评估ERNA-101在卵巢和乳腺癌模型中诱导和调节抗肿瘤免疫的能力
Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models
Eterna Therapeutics启动研究,以评估ERNA-101在卵巢癌和乳腺癌模型中诱导和调节抗肿瘤免疫的能力